BioSpace News Archive

Amicus Therapeutics today announced financial results for the full-year ended December 31, 2022.

Cidara Therapeutics, Inc. today announced promising efficacy and safety data from a planned interim analysis of the ongoing Phase 2a trial evaluating the pre-exposure prophylactic activity of CD388 against the H3N2 influenza A virus strain, as of a February 13, 2023 data cut-off.

Amarin Corporation plc today announced financial results for the quarter and year ended December 31, 2022 and provided an update on the Company’s operations.

Biogen Canada Inc. is pleased to announce that PrBYOOVIZ™, the first biosimilar referencing PrLUCENTIS® is now available in Canada to treat serious eye disorders including neovascular age-related macular degeneration, which can lead to rapid vision loss.

Elevation Oncology, Inc. today announced that management will participate in the following investor conferences in March.

Paragon Genomics announced a partnership with Devyser, a world leader in diagnostic kits and solutions for advanced DNA testing, to distribute its CleanPlex® products and technology in Italy, with the option to expand into additional territories.

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in the Leukemia Panel at the Cowen 43rd Annual Health Care Conference in Boston, MA on Wednesday, March 8, 2023 at 12:50 p.m. ET.

Novocure (NASDAQ: NVCR) today announced that the final patient has enrolled in the pivotal METIS study evaluating the efficacy of Tumor Treating Fields (TTFields) therapy following stereotactic radiosurgery (SRS) for treatment of patients with brain metastases resulting from non-small cell lung cancer (NSCLC).

CareDx, Inc. today announced that it is sponsoring the National Kidney Foundation (NKF) Annual Kidney Patient Summit taking place on Capitol Hill on March 1-2, 2023.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.